Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.

The pharmacogenomics journal - 1 Aug 2021

Shiota Masaki, Akamatsu Shusuke, Narita Shintaro, Sumiyoshi Takayuki, Fujiwara Maki, Uchiumi Takeshi, Ogawa Osamu, Habuchi Tomonori, Eto Masatoshi

Abstract excerpt

Missense polymorphism in HSD3B1, encoding 3β-hydroxysteroid dehydrogenase-1, was associated with outcome after abiraterone treatment. Other androgen-metabolizing enzymes may be involved in therapeutic effect in abiraterone. In this study, we investigated the significance of polymorphisms in genes involved in androgen and abiraterone metabolisms in prostate cancer patients treated with abiraterone. A total of 99...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Androstenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Association Studies

Share to Membrane Proteins

Share to Multienzyme Complexes

Share to Prostatic Neoplasms, Castration-Resistant

Share to Steroid Isomerases

Share to Treatment Failure

Source

Identifiers

PMID: 33649516
DOI: 10.1038/s41397-021-00220-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer.PMID 33649516Read ↗

Association of Missense Polymorphism inHSD3B1With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or AbirateroneSemantic proximity Read ↗

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studiesSemantic proximity Read ↗

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneSemantic proximity Read ↗

CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity Read ↗

CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.Semantic proximity Read ↗

HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer.Semantic proximity Read ↗

HSD3B1 variant and androgen-deprivation therapy outcome in prostate cancer.Semantic proximity Read ↗

Variant allele of HSD3B1 increases progression to castration-resistant prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.